Peer-reviewed article
Equivalent effectiveness of a prescription binocular treatment for amblyopia in real-world practice.
Gaier ED, Bohnsack BL, Bodack MI, Ghasia F, Hancock SE et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This study compares the real-world effectiveness of a prescription binocular treatment for amblyopia (a vision condition in children) delivered via head-mounted display against results from a controlled clinical trial. The researchers matched 40 children from a patient registry to the trial's criteria and found that visual acuity improvements were statistically equivalent to the trial results. The treatment appears to work similarly well in routine clinical practice as it did in the controlled research setting.
Key points
- Mean visual acuity improvement of 1.7 lines in registry patients versus 1.8 lines in RCT participants
- 40 children in real-world registry matched RCT eligibility criteria (age, amblyopia type and severity, prior treatment exposure)
- Results met statistical equivalence within the prespecified ±0.75-line margin
- No adverse safety events were reported
- 53% of registry patients had prior treatment exposure
Limitations
The study is a retrospective analysis of a small registry sample (n=40) and does not evaluate long-term outcomes beyond 12 weeks. The findings are limited to the US context and this specific prescription binocular treatment device.
Abstract
Background Gaps often exist between a therapy's performance in a controlled research setting and outcomes in routine clinical practice. A prescription binocular treatment delivered via head-mounted display has demonstrated efficacy for improving visual acuity in children with amblyopia in a pivotal randomized controlled trial (RCT). A retrospective patient registry has been established to collect real-world data on the treatment. Objective To evaluate the real-world effectiveness of this treatment by benchmarking outcomes from a patient registry against those from the RCT. Methods A retrospective analysis of a multicenter US patient registry was completed. The Registry was queried for patients who matched key eligibility criteria of the RCT with respect to age, amblyopia type and severity, and prior treatment exposure. The primary outcome was the change in amblyopic eye best-corrected visual acuity from baseline to the 12-week follow-up visit. These outcomes were compared with the historical intent-to-treat cohort (n = 45) from the RCT using a two one-sided tests procedure for equivalence with an equivalence margin of ±0.75 lines. Results Among the 40 registry patients meeting query criteria, mean age was 5.7 ± 1.0 years, and 21/40 (53%) had a history of prior treatment. Amblyopic eye best-corrected visual acuity improved a mean 1.7 lines (95% CI = 1.2-2.2), consistent with statistical equivalence within the prespecified ±0.75-line margin compared with RCT participants (1.8 lines; 95% CI = 1.4-2.3; two one-sided tests P = 0.038). No adverse safety events were reported. Conclusions Patients prescribed this treatment for amblyopia in clinical practice achieved visual acuity improvements consistent with those observed in the RCT, indicating that effectiveness generalizes to real-world settings.